Pt. 2. Supplementary exhibits and index to parts 1 and 2.
pt. 3. The Bureau of Medicine in the Food and Drug Administration.
pt. 4. Testimony and exhibits (including subsequent correspondence) on specialized drugs and drug problems: 1) drugs for mental illness; 2) antibiotics; 3) drug testing; 4) neonatal pharmacology; and 5) communication on drug emergencies.
pt. 5. Testimony and exhibits (including subsequent correspondence) on: 1) Commission on Drug safety; 2) Pharmaceutical Manufacturers Association; 3) Medical education on drug therapy and other drug issues.